WEBULL
WebtradeDownload

United Therapeutics (UTHR) Gets FDA Backing On Pulmonary Pipeline As Fair Value Stays In Focus

Simply Wall St · 2d ago

United Therapeutics (UTHR) has put fresh attention on its pulmonary pipeline after the FDA accepted its New Drug Application for ralinepag in pulmonary arterial hypertension and a supplemental filing for nebulized treprostinil in idiopathic pulmonary fibrosis.

That regulatory progress comes after a strong run for United Therapeutics, with a 1-month share price return of 9.31% and a 1-year total shareholder return of 25.32%, while the 3-year total shareholder return of 129.51% points to momentum that has been sustained over a longer period.

Scan how United Therapeutics fits into the wider pulmonary and biotech opportunity set by lining it up against 20 high quality undiscovered gems that are still flying under most investors' radars.

After a sharp move on fresh FDA momentum, United Therapeutics now forces a simple timing call. Is it worth paying up today, or does patience for a different entry make more sense once you look at the valuation work?

Most Popular Narrative: 15% Undervalued

Against a last close of $543.40, the most followed narrative anchors United Therapeutics at a fair value of about $637.92, which frames the recent FDA news inside a broader long term earnings and cash flow story built on pulmonary drugs and organ technologies.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

See why 33 investors see United Therapeutics as 15% undervalued.

Result: Fair Value of $637.92 (UNDERVALUED)

Still, the United Therapeutics story can change quickly if key trials disappoint, or if rival pulmonary therapies pressure Tyvaso and ralinepag more than analysts expect.

Find out about the key risks to this United Therapeutics narrative.

Next Steps

Sentiment around United Therapeutics is clearly optimistic. Move quickly, review the numbers yourself, and see how the story lines up with your expectations by examining the 3 key rewards.

Looking for more United Therapeutics style investment ideas?

If United Therapeutics has sharpened your focus, do not stop at one ticker. Broaden your watchlist now using targeted screeners that surface opportunities other investors might overlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.